Due to its immunostimulatory properties in activating murine and human DC and the induction of TLR3/RIG-I mediated antitumor immunity, PLGA particle-based cancer immunotherapy with Riboxxim demonstrated great proficiency for potential use in tumor vaccination—also in combination therapy with immune checkpoint inhibition by demonstrating reactivation of PLGA-particle-elicited antitumor T cells. Here, TLR3 is linked to neoplasm.